Recurrent Breast Cancer Completed Phase 4 Trials for Everolimus (DB01590)

Also known as: Breast Cancer Recurrent / Breast cancer NOS recurrent / Carcinoma breast recurrent / Breast carcinoma recurrent / Breast carcinoma NOS recurrent

IndicationStatusPhase
DBCOND0028640 (Recurrent Breast Cancer)Completed4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02248571Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With BevacizumabOther